Form ARS Allogene Therapeutics, For: Dec 31
ATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Allogene's CAR T therapy shows 31% response rate in kidney cancer
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- Earth Science Tech Inc. (ETST) Leveraging Technology and Strategic Positioning to Advance the Industry and Stamp Its Market Position
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share